Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

5 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 4
5(100.0%)
5Total
Phase 4(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06228456Phase 4Recruiting

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

Role: collaborator

NCT04668144Phase 4Completed

Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI

Role: collaborator

NCT03774394Phase 4Completed

Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus

Role: collaborator

NCT04634162Phase 4Completed

PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment

Role: collaborator

NCT03489863Phase 4Completed

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

Role: collaborator

All 5 trials loaded